

# A cyclic-RGD-BioShuttle functionalized with TMZ by DARinv “Click Chemistry” targeted to $\alpha_v\beta_3$ integrin for therapy

Klaus Braun, Manfred Wiessler, Rüdiger Pipkorn, Volker Ehemann, Tobias Bäuerle, Heinz Fleischhacker, Gabriele Müller,  
Peter Lorenz, Waldemar Waldeck

### Abstract :

Clinical experiences often document, that a successful tumor control requires high doses of drug applications. It is widely believed that unavoidable adverse reactions could be minimized by using gene-therapeutic strategies protecting the tumor-surrounding healthy tissue as well as the bone-marrow. One new approach in this direction is the use of “Targeted Therapies” realizing a selective drug targeting to gain effectual amounts at the target site, even with drastically reduced application doses. MCF-7 breast cancer cells expressing the  $\alpha_v\beta_3$  [alpha(v)beta(3)] integrin receptor are considered as appropriate candidates for such a targeted therapy. The modularly composed BioShuttle carrier consisting of different units designed to facilitate the passage across the cell membranes and for subcellular addressing of diagnostic and/or therapeutic molecules could be considered as an eligible delivery platform. Here we used the cyclic RGD-BioShuttle as a carrier for temozolomide (TMZ) at the  $\alpha_v\beta_3$  integrin receptor realizing local TMZ concentrations sufficient for cell killing. The IC<sub>50</sub> values are 12  $\mu\text{Mol/L}$  in the case of cRGD-BioShuttle-TMZ and 100  $\mu\text{Mol/L}$  for underivatized TMZ, which confirms the advantage of TMZ reformulation to realize local concentrations sufficient for cell killing.

### Key Word :

*Volume 7, Number 6, - 2010*